We built the first link between GABRP and gemcitabine in pancreatic cancer, and we report, for the first time, that GABRP might be downstream of the CD44 effector gene in gemcitabine-resistant pancreatic cancer cells. The gene discussed is CD44; the disease is pancreatic neoplasm.